FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine, namely to virology, hepatology, and can be used for treatment or prevention of viral hepatitis C infection. For this purpose therapeutically efficient amount of 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucin) cyclosporine or its pharmaceutically acceptable salt or solvate in combination with therapeutically efficient amount of second preparation is introduced to patient. Second preparation is selected from modulators of protease NS3-4A, nucleoside modulators RNA-dependent RNA-polymerase NS5B, non-nucleoside modulators RNA-dependent RNA-polymerase NS5B, riboflavin and immunomodulating medications. Also claimed are pharmaceutical compositions and sets.
EFFECT: introduction of claimed combinations of medications makes it possible to achieve high virologic response.
17 cl, 1 tbl, 8 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CYCLOSPORIN DERIVATIVES, SUBSTITUTED WITH 3-ETHER AND 3-THIOETHER FOR TREATING AND PREVENTING INFECTIOUS HEPATITIS C | 2005 |
|
RU2399628C2 |
| COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF VIRAL DISEASES | 2009 |
|
RU2519947C2 |
| HEMI-SULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS | 2018 |
|
RU2787616C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| APPLICATION OF CYCLOSPORINE AND PEGYLATED INTERFERON COMBINATION FOR HEPATITIS (HCV) TREATMENT | 2005 |
|
RU2394589C2 |
| BIS-BENZIMIDAZOLE DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | 2010 |
|
RU2540897C2 |
| MACROCYCLIC HEPATITIS C INHIBITORS | 2006 |
|
RU2436787C2 |
| NUCLEOSIDE INHIBITORS OF RNA-POLYMERASE HCV NS5B, METHODS FOR PRODUCTION AND USE THEREOF | 2014 |
|
RU2567854C1 |
| AMORPHOUS SALT OF MACROCYCLIC HCV INHIBITOR | 2010 |
|
RU2536868C2 |
| HEPATITIS C VIRUS MACROCYCLIC INHIBITORS | 2006 |
|
RU2486189C2 |
